Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce

Longeveron (LGVN) announced that the International Nonproprietary Names – INN – Expert Committee of the World Health Organization, or WHO, approved “laromestrocel” for the non-proprietary name of the company’s cellular therapy Lomecel-B. Commonly referred to as a generic name, each INN is a unique name used to identify pharmaceutical substances or active pharmaceutical ingredients. Lomecel-B is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer’s disease and hypoplastic left heart syndrome, a rare pediatric disease and orphan indication. The U.S. FDA has granted Lomecel-B Regenerative Medicine Advanced Therapy designation and Fast Track designation for the treatment of mild Alzheimer’s disease, and Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the treatment of HLHS.